Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681532 | 0.84 | KMT2A (0.62) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL2876686 | 0.79 | KMT2A (0.68) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL4161667 | 0.79 | KMT2A (0.58) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL27950143 | 0.77 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| Potassium Ion SCHEMBL3924936 | 0.76 | KMT2A (0.64) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL1148409 | 0.75 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL5899427 | 0.75 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL4589706 | 0.75 | SMN1; SMN2 (0.63) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL8264853 | 0.75 | PRMT5 (0.61) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL9580710 | 0.75 | KMT2A (1.00) | KMT2AGAAHTTCA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | KMT2A 3814/4885GAA 1387/4885HTT 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.